Cervomed Inc CRVO

$1.75 -0.46 (-20.81%)

Valuation

Market cap
33,413,000
Revenue TTM
$4,010,000
Net income TTM
$-26,970,000
PE ratio
0.00
Forward PE
—
Profit margin
-672.57%
Debt to equity
0.00

Trading

Volume
1,168,000
Avg volume
250,498
Day's range
$1.66 – $2.18
Shares out
15,119,000
Stochastic %K
12%
Beta
-0.75
Analysts
Strong Sell
Price target
$18.00

Price

Company profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease...

Show more

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 744 4400
Website
https://www.cervomed.com
Address
20 Park Plaza, Suite 424, Boston, United States

Latest news

Stocktwits

Adorno99 Oct 29, 11:40 PM
$CRVO who wants to see HC Wainwright reiterate their 25 dollar price target? 😄
1 replies
walker7782 Oct 29, 9:54 PM
$CRVO While early trial data was known, today’s formal peer-reviewed publication confirmed the Phase 2b primary endpoint miss. Today's PR also revealed CervoMed cannot fund Phase 3 alone and is seeking a partner, triggering institutional dumping and a liquidity vacuum on financing risk. Institutions are not jumping in, they jumped out. Big pharma won’t touch this without significant contributions from CRVO which means dilution for sure. So yes it tanked on “old data” but this was a full picture confirmation. If it was just a random journal publishing old news then it wouldn’t drop this hard. There is no institutional support and the dead cat bounce fell off hard. This wasn’t a drop on trial data so much as it was on a lack of financial stability.
2 replies
Orlandotrader Oct 29, 8:13 PM
$CRVO accurate. The primary endpoint of the Phase 2b RewinD-LB trial (change in the Clinical Dementia Rating Scale - Sum of Boxes, or CDR-SB) was missed in the initial 16-week placebo-controlled phase due to a drug product manufacturing issue that resulted in a defective drug batch (referred to as "Batch A") with decreased bioavailability and drug exposure. The announcement made on October 29, 2026, by CervoMed (NASDAQ: CRVO) is primarily a publication of existing data rather than entirely new trial results. Wow Mr market just slammed this on Old Data!!!!! Let’s see what New Data brings in November? CervoMed noted that actual new clinical data—specifically the 24-week biomarker data from its Phase 2a nfvPPA trial—is scheduled to be presented in November 2026 at the CTAD conference.
1 replies
buymoremakemore Oct 29, 7:58 PM
$CRVO Patrick Stewart just died today of Lewy Body. Get this drug on the fucking market
0 replies
SolNur Oct 29, 7:30 PM
$CRVO Alright, hoping this helps with everyone that wants to know what is going today: There was news today, but it was not a new Phase 2b readout. Today CRVO announced the peer-reviewed publication of the already-known RewinD-LB Phase 2b DLB results. The overall primary endpoint miss was previously known. It did not fail today. The new publication provides the full analysis, including evidence that lower drug exposure may have contributed to the miss and that higher exposure patients showed better results. The November data are a completely different trial: the ongoing Phase 2a nfvPPA study. CRVO still expects 24-week biomarker data at CTAD in November. Also, RESTORE stroke results have not been released yet. So today’s news = new publication of old DLB trial results + additional supporting analysis, not a new clinical failure and not the November readout. The drop is just market responding to the peer review and small caps get hit like this.
2 replies
Hugoooo Oct 29, 7:26 PM
$CRVO We are writing to let you know that the underlying asset for your position in CervoMed Inc (CRVO) has been moved to sell-only. This change happened because the security fell below minimum listing requirements.Do I need to do anything?Because our platform does not support ongoing positions in securities that fail the minimum listing requirements, you must close all open positions for CervoMed Inc (CRVO) by market close on 3.11.2026. Any positions remaining open after this deadline will be automatically liquidated at market price.Where can I get help?If you have any questions regarding this update, you can contact us via the 24/7 chat . that’s the reason ？email from revolut
3 replies
StellaLunaSun Oct 29, 7:22 PM
$CRVO Could someone be so kind as to explain this to me? Someone who is very familiar with this topic? I'm very knowledgeable about other stocks, but this is kind of "uncharted territory".Was there any news today or not? Was that old news? Shouldn't the 2b be released in November? The 2a ones were okay.That's why I don't understand: are these news items really new today, or are they old news?I would be very grateful for a little help. 😀
1 replies
BPler Oct 29, 6:55 PM
$CRVO no way, Armistice Capital is not behind this ...
1 replies